Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (30)

B-03Thierry Buclin

Meeting clinicians’ and patients’ needs in the practice of therapeutic monitoring

Wednesday 09:00-09:20

B-04Catherine Sherwin

Model-based Dose Individualization Approaches Using Biomarkers

Wednesday 09:20-09:50

B-05Ron Keizer

Experiences in applied clinical pharmacometrics: challenges, recommendations, and research opportunities

Wednesday 09:50-10:10

B-07Maddalena Centanni

A pharmacometric framework for dose individualisation of sunitinib in GIST

Wednesday 11:40-12:00

B-08

Use of mathematical modeling for optimizing and adapting immunotherapy protocols in HIV-infected patients

Wednesday 12:00-12:20

B-09Mouna Akacha

Background on estimands and why are they important?

Wednesday 12:20-12:35

B-10Michael Looby

PMX perspective on Estimands

Wednesday 12:35-12:50

B-13Camille Vong

Power assessment for hierarchical combination endpoints using joint modelling of repeated time-to-event and time-to-event models versus Finkelstein-Schoenfeld method

Wednesday 14:30-14:50

B-14Yixuan Zou

A novel score test-based method for efficient covariate selection in population pharmacokinetic analysis

Wednesday 14:50-15:10

B-15Qing Xi Ooi

Evaluation of assumptions underpinning pharmacometric models

Wednesday 15:10-15:30

B-16Mats Karlsson

Extensive and automatic assumption assessment of pharmacometric models

Wednesday 15:30-15:50

B-18Oskar Alskär

An integrated glucose homeostasis model of glucose, insulin, C-peptide, GLP-1, GIP and glucagon in healthy subjects and patients with Type 2 diabetes

Wednesday 17:20-17:40

B-19Daniel Hill-McManus

Application of a linked pharmacometric/pharmacoeconomic model to assess the impact of non-adherence: Application to the treatment of gout

Wednesday 17:40-18:00

C-01Simon Buatois

A pharmacometric extension of MCP-MOD in dose finding studies

Thursday 08:30-08:50

C-02Benjamin Guiastrennec

New dosing recommendations for anti-tuberculosis therapy in Indian children

Thursday 08:50-09:10

C-03Jurgen Langenhorst

Cause-specific hazard models with markovian elements to quantify the fludarabine exposure-response relationship: from learning to confirming in allogeneic hematopoietic cell transplantation

Thursday 09:10-09:30

C-04Gustaf Wellhagen

A bounded integer model for rating and composite scale data

Thursday 09:30-09:50

C-07Phyllis Chan

Assessment of a model to correlate early tumor size response to overall survival in relapsed or refractory diffuse large B cell lymphoma patients

Thursday 11:30-11:50

C-08Rui Zhu

Exposure-response (E-R)-based product-profile (PP)-driven clinical utility index (CUI) to support phase III dose selection in oncology

Thursday 11:50-12:10

C-09Zinnia Parra-Guillen

A quantitative modelling framework to inform dose selection of Xentuzumab, a dual insulin-like growth factor-I/II neutralizing antibody in cancer patients

Thursday 12:10-12:30

C-12Scott Pruitt

Clinical Overview of Immunotherapy in Oncology

Thursday 14:10-14:40

C-13Benjamin Ribba

Drug response variability and optimal dosing in immuno-oncology

Thursday 14:40-15:10

C-15Rukmini Kumar

Predicting response and identifying responders to combination cancer immunotherapy in melanoma using Quantitative Systems Pharmacology (QSP) models

Thursday 16:40-17:00

C-16Hanna Silber Baumann

PKPD analysis of soluble CD25 to characterize the concentration-effect relationship observed following the administration of Cergutuzumab Amunaleukin, a targeted immunocytokine for cancer immunotherapy

Thursday 17:00-17:20

D-01David Ternant

Population and Bayesian kinetic modelling of necrosis biomarkers to assess the effect of conditioning therapies on infarct size

Friday 09:15-09:35

D-02João Abrantes

Integrated modelling of factor VIII activity kinetics, occurrence of bleeds and individual characteristics in haemophilia A patients using a full random effects modelling (FREM) approach

Friday 09:35-09:55

D-03Elin Boger

A partial differential equation approach to inhalation PBPK modelling

Friday 09:55-10:15

D-04Chihiro Hasegawa

Simplification of multi-scale systems models for data-driven analyses: what has progressed in these 5 years?

Friday 10:15-10:35

D-08Sulav Duwal

A multiscale systems pharmacology framework to predict drug-class specific prophylactic efficacy of antivirals against HIV

Friday 11:30-11:50

D-09Vincent Madelain

Ebola viral dynamics in nonhuman primates: insights into virus immuno-pathogenesis and antiviral strategies

Friday 11:50-12:10